Mizner Bioscience LLC reported on Wednesday the receipt of the first approval for a therapeutically equivalent generic version of Clomipramine Hydrochloride Tablets from the US Food and Drug Administration's (FDA) Abbreviated New Animal Drug Application (ANADA) pathway.
Clomipramine Hydrochloride Tablets are used as part of a comprehensive behavioural management programme to treat separation anxiety in dogs over six months of age.
Following the FDA's approval, the company will launch its Clomipramine Hydrochloride Tablets in 5mg, 20mg, 40mg and 80mg with immediate effect.
According to the company, the tablet is the equivalent generic version of Elanco's Clomicalm (Clomipramine Hydrochloride Tablets).
Shanton Pharma completes SAP-001 End-of-Phase 2 meeting with US FDA
Eli Lilly's single-injection, once-monthly maintenance Omvoh regimen receives US FDA approval
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Spinogenix to present SPG601 Phase 2a trial results at AACAP Conference
AnnJi Pharmaceutical secures FDA Fast Track Designation for AJ201 in rare neuromuscular disease
Myosin Therapeutics' MT-125 granted US FDA Fast Track designation in glioblastoma
Boehringer Ingelheim's JASCAYD (nerandomilast) IPF treatment gains Chinese regulatory approval
Galera Therapeutics sells dismutase mimetics portfolio to Biossil in USD108.5m agreement
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis